2021

1. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

   npj Precision Oncology, Vol. 5, Núm. 1

2. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

   npj Breast Cancer, Vol. 7, Núm. 1